(ZURA) Zura Bio Ordinary Shares - Ratings and Ratios
Tibulizumab, Torudokimab, Crebankitug
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 137% |
| Value at Risk 5%th | 198% |
| Relative Tail Risk | -11.88% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.58 |
| Alpha | 235.30 |
| CAGR/Max DD | -0.09 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.560 |
| Beta | 1.479 |
| Beta Downside | 1.644 |
| Drawdowns 3y | |
|---|---|
| Max DD | 97.00% |
| Mean DD | 87.26% |
| Median DD | 88.56% |
Description: ZURA Zura Bio Ordinary Shares December 22, 2025
Zura Bio Limited (NASDAQ: ZURA) is a clinical-stage biotech focused on novel immunotherapies for immune-mediated and inflammatory diseases in the United States. Founded in 2022 and based in Henderson, Nevada, the company trades as a common stock under the GICS sub-industry “Biotechnology.”
The lead asset, **Tibulizumab**, is a bispecific IgG-scFv antibody that simultaneously blocks IL-17A and BAFF (B-cell activating factor). It is currently in a Phase 2 trial targeting indications such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus. Zura’s pipeline also includes **Torudokimab (ZB-880)**, an IL-33 neutralizing monoclonal antibody that has completed Phase 1/2 studies, and **Crebankitug (ZB-168)**, an IL-7Rα antagonist that finished Phase 1/1b trials, both aimed at broader inflammatory and autoimmune indications.
Key market-level observations: (1) The U.S. biologics market for autoimmune disorders is projected to grow at a CAGR of ~7% through 2028, driven by rising prevalence of conditions like psoriasis and lupus. (2) Zura reported a cash runway of approximately 12 months as of its latest 10-Q, with R&D expenses accounting for ~45% of total outflows-typical for a company at this stage. (3) Peer-group analysis shows that Phase 2 bispecific antibodies in the IL-17/BAFF space have historically achieved median forward-price multiples of 12×–15× upon successful Phase 3 read-out, indicating a potentially high upside if Tibulizumab meets its efficacy endpoints.
Given the early-stage nature of Zura’s assets and the limited public financial history, investors should treat any valuation as highly speculative and weigh the probability-adjusted return against the company’s cash burn and upcoming trial milestones.
For a deeper, data-driven look at ZURA’s risk-adjusted upside, you might find the analyst tools on ValueRay useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-62.5m TTM) > 0 and > 6% of Revenue (6% = 120.0 TTM) |
| FCFTA -0.37 (>2.0%) and ΔFCFTA -23.24pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.37 (>3.0%) and CFO -53.4m > Net Income -62.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (94.6m) change vs 12m ago 8.28% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.00% (prev 0.0%; Δ 0.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -17.77 (EBITDA TTM -68.9m / Interest Expense TTM -3.88m) >= 6 (WARN >= 3) |
Altman Z'' -10.70
| (A) 0.81 = (Total Current Assets 142.3m - Total Current Liabilities 25.5m) / Total Assets 143.9m |
| (B) -1.44 = Retained Earnings (Balance) -207.4m / Total Assets 143.9m |
| warn (B) unusual magnitude: -1.44 — check mapping/units |
| (C) -0.41 = EBIT TTM -69.0m / Avg Total Assets 166.5m |
| (D) -8.13 = Book Value of Equity -207.4m / Total Liabilities 25.5m |
| Total Rating: -10.70 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.55
| 1. Piotroski 0.0pt |
| 2. FCF Yield -32.24% |
| 3. FCF Margin data missing |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda 2.02 |
| 6. ROIC - WACC (= -53.35)% |
| 7. RoE -48.17% |
| 8. Rev. Trend 22.89% |
| 9. EPS Trend -2.63% |
What is the price of ZURA shares?
Over the past week, the price has changed by +17.69%, over one month by +45.29%, over three months by +85.88% and over the past year by +253.07%.
Is ZURA a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ZURA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.6 | 146.8% |
| Analysts Target Price | 15.6 | 146.8% |
| ValueRay Target Price | 7.5 | 17.9% |
ZURA Fundamental Data Overview January 17, 2026
Revenue TTM = 2000 USD
EBIT TTM = -69.0m USD
EBITDA TTM = -68.9m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -139.0m USD (from netDebt column, last quarter)
Enterprise Value = 165.9m USD (305.0m + (null Debt) - CCE 139.0m)
Interest Coverage Ratio = -17.77 (Ebit TTM -69.0m / Interest Expense TTM -3.88m)
EV/FCF = -3.10x (Enterprise Value 165.9m / FCF TTM -53.5m)
FCF Yield = -32.24% (FCF TTM -53.5m / Enterprise Value 165.9m)
FCF Margin = -2.68m% (FCF TTM -53.5m / Revenue TTM 2000 )
Net Margin = -3.13m% (Net Income TTM -62.5m / Revenue TTM 2000 )
Gross Margin = -1850 % ((Revenue TTM 2000 - Cost of Revenue TTM 39.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.15 (Enterprise Value 165.9m / Total Assets 143.9m)
Interest Expense / Debt = unknown (Interest Expense -3.88m / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -54.5m (EBIT -69.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.58 (Total Current Assets 142.3m / Total Current Liabilities 25.5m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = 2.02 (negative EBITDA) (Net Debt -139.0m / EBITDA -68.9m)
Debt / FCF = 2.60 (negative FCF - burning cash) (Net Debt -139.0m / FCF TTM -53.5m)
Total Stockholder Equity = 129.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.55% (Net Income -62.5m / Total Assets 143.9m)
RoE = -48.17% (Net Income TTM -62.5m / Total Stockholder Equity 129.8m)
RoCE = -58.24% (EBIT -69.0m / Capital Employed (Total Assets 143.9m - Current Liab 25.5m))
RoIC = -41.99% (negative operating profit) (NOPAT -54.5m / Invested Capital 129.8m)
WACC = 11.36% (E(305.0m)/V(305.0m) * Re(11.36%) + (debt-free company))
Discount Rate = 11.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 41.77%
Fair Price DCF = unknown (Cash Flow -53.5m)
EPS Correlation: -2.63 | EPS CAGR: -2.12% | SUE: 1.33 | # QB: 1
Revenue Correlation: 22.89 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.19 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-0.78 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=-2.6% | Growth Revenue=+0.0%
Additional Sources for ZURA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle